Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Lilly’s new obesity pill passes heart safety test in diabetes

 April 16, 2026

BioPharma Dive

The findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes.

Clinical DataMetabolic & GLP-1Read full story

Post navigation

Lilly debuts more Foundayo data as FDA requests post-marketing trials →
← FDA moves toward easing restrictions on certain peptides

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com